September is Pulmonary Fibrosis Awareness Month, and the American Lung Association today announced a new educational program to help people living with pulmonary fibrosis (PF) and their loved ones ...

Fibrosis of the lungs is often a silent disease until it's too late. By the time patients are diagnosed, the scarring of ...

Strategies that combine ferroptosis inhibition with established antifibrotics could ultimately move treatment from slowing progression to truly reversing fibrosis, new research suggests.

Fibrosis of the lungs is often a silent disease until it's too late. By the time patients are diagnosed, the scarring of ...

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by the accumulation of scar tissue in the ...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a ...

In a study published in Aging on Aug. 8, 2025, researchers at Insilico Medicine unveiled AI-powered models that uncover shared biological pathways between IPF and the aging process, pointing to novel ...

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market is projected to grow from USD 5.917 billion in 2025 to USD ...

Pulmonary Fibrosis/Interstitial Lung Disease Mission The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients ...

Advancing IPF Care: New Evidence and Economic Considerations in Treatment Decision-Making Learn about the clinical and economic burden of idiopathic and progressive pulmonary fibrosis; the need ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients with idiopathic pulmonary fibrosis in Korea.Recently, the number of ...